Advertisement

Medical Oncology and Tumor Pharmacotherapy

, Volume 9, Issue 2, pp 101–105 | Cite as

P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine a containing protocols

  • Meral Beksac
  • Hamd Akan
  • Haluk Ko
  • Osman Lhan
  • Ehsuvar Ertürk
  • Aynur Güneyl
  • Yem Kzünal
  • Orhan S.arda
Article
  • 17 Downloads

Abstract

Either p-glycoprotein (pgp) or the encoding gene mdrl expression has been reported to be correlated with multidrug resistance and poor treatment response. To investigate the incidence of pgp in refractory hematological neoplasms we analyzed malignant cells from 40 patients by an immunoperoxidase method using the monoclonal antibody C219. Pgp was positive in 75 % of acute nonlymphoblastic leukemia (ANLL) and 50 % of acute lymphoblastic leukemia (ALL). Pgp positivity was similarly distributed in both Tdt (-) and (+) ANLLs (64 % versus 100 %). Addition of Verapamil (VRP) (12 patients) or Cyclosporine A (CsA) (7 patients) to the previous chemotherapy protocol resulted in complete response in 7 (58 %) and 3 (43 %) of the patients respectively. Partial response was observed in one patient who received CsA. Both chemosensitizers were tolerated well with few reversible side effects. The preliminary results of this study have been presented in the 15th International Cancer Congress, August 1990-Hamburg, Germany.

Key Words

P-glycoprotein Verapamil Cyclosporine A Refractory hematological neoplasms 

Abbreviations

PGP

P-glycoprotein

VRP

Verapamil

CsA

Cyclosporine A

ALL

Acute lymphoblastic leukemia

ANLL

Acute non-lymphoblastic leukemia

CML-bc

Chronic myelogenous leukemia-blastic crisis

CLL

Chronic lymphocytic leukemia

MM

Multiple myeloma

Am

Amsacrine

A

Doxorubicine

O

Vincristine

Ara-C

Cytosine Arabinoside

M

Mitoxantrone

Ac

Aclarubicine

C

Cyclophosphamide

P

Prednisolone

D

Dexamethasone

AlloBMT

Allogeneic Bone Marrow Transplantation

AutoBMT

Autologous Bone Marrow Transplantation

PR

Partial response

CR

Complete remission

NR

No response

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sato H, Preisler H D, Gottesman M: Expression of multidrug resistance gene in the cells of patients with ANLL.Blood 72(5) (suppl) 244a (1989).Google Scholar
  2. 2.
    Holmes J A, West R R, Whittaker J A, Jacobs A: Correlation of mdr status with clinical outcome in patients with acute myeloblastic leukemia.Br J Haematol 77, 130–131 (1991).PubMedCrossRefGoogle Scholar
  3. 3.
    Marie J P, Zittoun R, Sikic B I: Multidrug resistance (mdrl) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity.Blood 78(3), 586–592 (1991).PubMedGoogle Scholar
  4. 4.
    Beksac M, Peterson C, Reizenstein P: Decreased retention of vinka alkaloids in chronic lymphatic leukemia cells from refractory patients.Cancer chemotherapy and pharmacology 15, 72–75 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Kartner N, Riordan J R, Ling V: Cell surface p-glycoprotein associated with multidrug resistance in mammalian cell lines.Science 221, 1285–1288 (1983).PubMedCrossRefGoogle Scholar
  6. 6.
    Goldstein L J, Galski H, Fojo A, Willingham M, Lai S L, Gazdar A, Pirker R, Green A, Crist W, Brodeur G M, Lieber M, Cossman J, Gottesman M M, Pastan I: Expression of a multidrug resistance gene in human cancer.J Natl Cancer Inst 81, 116–124(1989).PubMedCrossRefGoogle Scholar
  7. 7.
    Holmes J, Jacobs A, Carter G, Janowska-Wieczobek A, Padua R A: Multidrug resistance in haemopoetic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia.Br J Haematol 72, 40–44 (1989).PubMedCrossRefGoogle Scholar
  8. 8.
    Kuwazuru Y, Yoshimura A, Harada S, Ichikawa M, Saito T, Uozomi K, Utsunomiya A, ArimaT, Akiyama S: Expression of the multidrug transporter, p-glycoprotein in chronic myelogenous leukemia in blastic crisis.Br J Haematol 74, 24–29(1990).PubMedCrossRefGoogle Scholar
  9. 9.
    Kato S, Nishimura J, Muta K, Yufu Y, Nawata H: Overex- pression of p-glycoprotein in adult T-cell leukemia.Lancet 336, 573(1990).PubMedCrossRefGoogle Scholar
  10. 10.
    Salmon S E, Dalton W S, Grogan T M, Pleiza P, Lenhert M, Roe D J, Miller T P: Multidrug resistant myeloma: Laboratory and clinical effects of verapamil as a chemosen- sitizer.Blood 78(1), 44–50 (1991).PubMedGoogle Scholar
  11. 11.
    Tsuro T, Lida H, Tsukagoshi S, Sakurai Y: Increased accumulation of vincristine and adriamycine in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.Cancer Res 42, 4730–4733 (1982).Google Scholar
  12. 12.
    Dalton W S: Reversing multidrug resistance in the laboratory clinic.Proceed Am Assoc Cancer Res 31, 520–521 (1990).Google Scholar
  13. 13.
    Yahanda A M, Adler K M, Hardy R, Brophy N A, Halsey J, Sikic B I: A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.Proceed Am Soc Clin Oncol 10, 102(1991).Google Scholar
  14. 14.
    Erlichman C, Bjamanson G, Bunting P, DeAngelis C, Kerr I, Maki E, Moore M, Rahemtulla C, Thiessen J, Walker S: Cyclosporine A modulation of doxorubicin: a pharmacokinetic /pharmacodynamic trial.Proceed Am Soc Clin Oncol 10, 111 (1991).Google Scholar
  15. 15.
    Durivage H T, Buzaid A C, Todd M B, Poo W J, Marsh J C, Davis C A, Hait W N: A phase I-H study of pulse Cyclosporine A plus vinblastine in selected refractory malignancies.Proceed Am Soc Clin Oncol 10, 116 (1991).Google Scholar
  16. 16.
    Cantwell B, Buamah P, Harris A L: Phase I and II study of verapamil and intravenous vindesine.Br J Cancer 52, 525 (1985).PubMedGoogle Scholar
  17. 17.
    List A F, Spier C M, Cline A, Doll D C, Garewal H, Morgan R, Sandberg A A: Expression of the multidrug resistance gene product (p-glycoprotein) in myelodysplasia is associated with a stem cell phenotype.Br J Haematol 78, 28–34 (1991).PubMedCrossRefGoogle Scholar
  18. 18.
    Holmes J, Jacobs A, Carter G, Whittaker J A, Bentley D, Padua R A:Is the mdr 1 gene relevant in chronic lymphocytic leukemia?Leukemia 4, 216–218 (1990).PubMedGoogle Scholar
  19. 19.
    Wiersma S R, Ortega J, Sobel E, Weinberg K I: Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood.N Eng J Med 324, 800–808(1991).CrossRefGoogle Scholar
  20. 20.
    Herweijer H, Sonneveld P, Baas F, Nooter K: Expression of mdr 1 and mdr 3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.J Natl Cancer Inst 82(13), 1133–1140(1990).PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1992

Authors and Affiliations

  • Meral Beksac
    • 1
  • Hamd Akan
    • 1
  • Haluk Ko
    • 1
  • Osman Lhan
    • 1
  • Ehsuvar Ertürk
    • 1
  • Aynur Güneyl
    • 1
  • Yem Kzünal
    • 1
  • Orhan S.arda
    • 1
  1. 1.Ankara Faculty of Medicineİbn-i Sina Hospital, Department of HematologyAnkaraTurkey (Türkiye)

Personalised recommendations